October 1, 2020 – Intalere (St. louis, MO) announced a new agreement with Tetraphase Pharmaceuticals, Inc. (Watertown, MA).
Through this agreement Intalere members will receive negotiated pricing on Tetraphase-branded novel antibiotics including XERAVA, approved for the treatment of complicated intra-abdominal infections (cIAI).
Tetraphase is tackling the challenging clinical threat presented by antimicrobial resistance by developing new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future.
This contract is currently effective through December 31, 2021.